Table 1.
Baseline characteristics of participants in the PIAAF-Pharmacy study
| Characteristics | ‘Actionable’ AF (n=29) | No AF (n=1116) | p Value |
|---|---|---|---|
| Age (years), mean (SD) | 77.2 (6.8) | 74.6 (6.8) | 0.04 |
| Male (%) | 17 (58.6) | 451 (40.4) | 0.05 |
| Hypertension (%) | 19 (65.5) | 572 (51.3) | 0.13 |
| Diabetes mellitus (%) | 7 (24.1) | 212 (19.0) | 0.49 |
| History of heart failure (%) | 2 (6.9) | 21 (1.9) | 0.11 |
| Vascular artery disease (%) | 4 (13.8) | 99 (8.9) | 0.32 |
| History of stroke or transient ischaemic attack (%) | 3 (10.3) | 97 (8.7) | 0.74 |
| History of sleep apnoea (%) | 2 (6.9) | 113 (10.1) | 0.76 |
| Average systolic BP (mm Hg) | 134.1 (17.1) | 139.6 (21.0) | 0.21 |
| Average diastolic BP (mm Hg) | 75.7 (12.3) | 76.3 (12.3) | 0.94 |
| Body mass index (kg/m2), mean (SD) | 26.9 (3.8) | 26.9 (4.9) | 0.63 |
| Heart rate, mean (SD) | 71.9 (10.4) | 71.1 (12.1) | 0.57 |
| CHA2DS2-VASc score=1 | 2 (6.9) | 100 (9.0) | 1.00 |
| CHA2DS2-VASc score ≥2 | 27 (93.1) | 1016 (91.0) | 1.00 |
| CANRISK categories (%) | |||
| Low risk | 2 (20) | 45 (9.3) | |
| Intermediate risk | 4 (40) | 227 (47.1) | 0.59 |
| High risk | 4(40) | 210 (43.6) | |
| Medication (%) | |||
| Diuretic | 8 (27.6) | 205 (18.4) | 0.21 |
| β-Blocker | 7 (24.1) | 183 (16.4) | 0.27 |
| Calcium channel blocker | 9 (31.0) | 169 (15.1) | 0.02 |
| Angiotensin receptor blocker | 6 (20.7) | 198 (17.7) | 0.68 |
| Insulin | 0 (0) | 43 (3.9) | 0.62 |
| Oral hypoglycaemic | 6 (20.7) | 153 (13.7) | 0.28 |
| Statins | 14 (48.3) | 464 (41.6) | 0.47 |
| α-Blocker | 0 (0) | 17 (1.5) | 1 |
| ACE inhibitor | 6 (22.2) | 213 (19.3) | 0.7 |
| Anti-arrhythmic | 0 (0) | 4 (0.4) | 1 |
| Anti-platelet agent | 1 (3.4) | 12 (1.1) | 0.28 |
AF, atrial fibrillation; BP, blood pressure; PIAAF-Pharmacy, Program for the Identification of ‘Actionable’ Atrial Fibrillation in the Pharmacy Setting.